Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today - 2Top 10 Smash hit Computer games of the Year
- 3Surge of off‑lease electric vehicles expected to drive down used EV prices
- 4Getting ready for a Mechanized World: 10 Positions That computer based intelligence Could Dominate
- 5Step by step instructions to Remain Spurred While Chasing after a Web-based Degree
- 'Women on the floor, riddled with bullets': Ex-hostage Rom Braslavski recounts 'horrors' of Oct. 7
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
- 10 Moves toward Start Your Own Effective Business
- What happened to Eleven after the ambiguous 'Stranger Things' series finale? Millie Bobby Brown knows — but 'swore herself to secrecy'
- What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
- China bans storing cremated remains in empty 'bone ash apartments'
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
- Scientists train to dive beneath polar ice as climate change warms the Arctic and Antarctica
